Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon in early Parkinson's disease (TEMPO-1)
NCT04201093Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of tavapadon in Parkinson's disease (PD), sponsored by AbbVie Inc.. Started Dec 2019; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04201093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201093.